Journal of Semnan University of Medical Sciences
Image Credit:Koomesh
Outline
Investigating the Effect of Atorvastatin on the Cisplatin-Induced Nephrotoxicity
Authors
Abstract
Background: Cisplatin nephrotoxicity is a major limiting factor in patients with solid tumors.
Objectives: We prospectively evaluated the nephroprotective effect of atorvastatin in humans receiving cisplatin.
Methods: Thirty patients, candidates for cisplatin administration, were included. Group 1 received atorvastatin 40 mg/d one hour
before cisplatin administration and continued for 7 days. Group 2 received placebo/d, starting 1 hour before cisplatin and continued
for 7 days. Blood samples were collected for BUN, creatinine, magnesium, and potassium on days 8 ,0, and 21 after receiving cisplatin.
Results: Glomerular filtration rate (GFR) changes between the two groups on the 8th day showed a statistically significant decrease
in the placebo group (GFR decreases from 27.96 ± 77.22 to 19.9 ± 64.25 with P-value = 0.016), but not in the atorvastatin group (GFR
decreases from 19.73 ± 69.59 to 21.43 ± 64.23 with P-value = 0.125).
Conclusion: Atorvastatin may have a reno-protective effect.
Highlights
References
- 1.Rozencweig M, von Hoff DD, Slavik M, Muggia FM. Cis-diamminedichloroplatinum (II). A new anticancer drug. Ann Intern Med. 1977;86(6):803-12. [PubMed ID:326117]. https://doi.org/10.7326/0003-4819-86-6-803.
- 2.Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of Cisplatin nephrotoxicity. Toxins (Basel). 2010;2(11):2490-518. [PubMed ID:22069563]. [PubMed Central ID:PMC3153174]. https://doi.org/10.3390/toxins2112490.
- 3.Kidera Y, Kawakami H, Sakiyama T, Okamoto K, Tanaka K, Takeda M, et al. Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection. PLoS One. 2014;9(7):e101902. [PubMed ID:25020203]. [PubMed Central ID:PMC4096506]. https://doi.org/10.1371/journal.pone.0101902.
- 4.Ozkok A, Edelstein CL. Pathophysiology of cisplatin-induced acute kidney injury. Biomed Res Int. 2014;2014:967826. [PubMed ID:25165721]. [PubMed Central ID:PMC4140112]. https://doi.org/10.1155/2014/967826.
- 5.Lebwohl D, Canetta R. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer. 1998;34(10):1522-34. [PubMed ID:9893623]. https://doi.org/10.1016/s0959-8049(98)00224-x.
- 6.Shiraishi F, Curtis LM, Truong L, Poss K, Visner GA, Madsen K, et al. Heme oxygenase-1 gene ablation or expression modulates cisplatin-induced renal tubular apoptosis. Am J Physiol Renal Physiol. 2000;278(5):F726-36. [PubMed ID:10807584]. https://doi.org/10.1152/ajprenal.2000.278.5.F726.
- 7.Madias NE, Harrington JT. Platinum nephrotoxicity. Am J Med. 1978;65(2):307-14. [PubMed ID:99034]. https://doi.org/10.1016/0002-9343(78)90825-2.
- 8.Stewart DJ, Dulberg CS, Mikhael NZ, Redmond MD, Montpetit VA, Goel R. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods. Cancer Chemother Pharmacol. 1997;40(4):293-308. [PubMed ID:9225947]. https://doi.org/10.1007/s002800050661.
- 9.Reece PA, Stafford I, Russell J, Khan M, Gill PG. Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J Clin Oncol. 1987;5(2):304-9. [PubMed ID:3806171]. https://doi.org/10.1200/JCO.1987.5.2.304.
- 10.Caglar K, Kinalp C, Arpaci F, Turan M, Saglam K, Ozturk B, et al. Cumulative prior dose of cisplatin as a cause of the nephrotoxicity of high-dose chemotherapy followed by autologous stem-cell transplantation. Nephrol Dial Transplant. 2002;17(11):1931-5. [PubMed ID:12401849]. https://doi.org/10.1093/ndt/17.11.1931.
- 11.Manohar S, Leung N. Cisplatin nephrotoxicity: a review of the literature. J Nephrol. 2018;31(1):15-25. [PubMed ID:28382507]. https://doi.org/10.1007/s40620-017-0392-z.
- 12.Miyoshi T, Uoi M, Omura F, Tsumagari K, Maesaki S, Yokota C. Risk Factors for Cisplatin-Induced Nephrotoxicity: A Multicenter Retrospective Study. Oncology. 2021;99(2):105-13. [PubMed ID:32966986]. https://doi.org/10.1159/000510384.
- 13.Peres LA, da Cunha AD. Acute nephrotoxicity of cisplatin: molecular mechanisms. J Bras Nefrol. 2013;35(4):332-40. [PubMed ID:24402113]. https://doi.org/10.5935/0101-2800.20130052.
- 14.dos Santos NA, Carvalho Rodrigues MA, Martins NM, dos Santos AC. Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update. Arch Toxicol. 2012;86(8):1233-50. [PubMed ID:22382776]. https://doi.org/10.1007/s00204-012-0821-7.
- 15.Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008;73(9):994-1007. [PubMed ID:18272962]. https://doi.org/10.1038/sj.ki.5002786.
- 16.Faubel S, Lewis EC, Reznikov L, Ljubanovic D, Hoke TS, Somerset H, et al. Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1beta, IL-18, IL-6, and neutrophil infiltration in the kidney. J Pharmacol Exp Ther. 2007;322(1):8-15. [PubMed ID:17400889]. https://doi.org/10.1124/jpet.107.119792.
- 17.Aydinoz S, Uzun G, Cermik H, Atasoyu EM, Yildiz S, Karagoz B, et al. Effects of different doses of hyperbaric oxygen on cisplatin-induced nephrotoxicity. Ren Fail. 2007;29(3):257-63. [PubMed ID:17497437]. https://doi.org/10.1080/08860220601166487.
- 18.Ozbek E, Cekmen M, Ilbey YO, Simsek A, Polat EC, Somay A. Atorvastatin prevents gentamicin-induced renal damage in rats through the inhibition of p38-MAPK and NF-kappaB pathways. Ren Fail. 2009;31(5):382-92. [PubMed ID:19839839]. https://doi.org/10.1080/08860220902835863.
- 19.Park JK, Muller DN, Mervaala EM, Dechend R, Fiebeler A, Schmidt F, et al. Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects. Kidney Int. 2000;58(4):1420-30. [PubMed ID:11012877]. https://doi.org/10.1046/j.1523-1755.2000.00304.x.
- 20.Khoshnoud MJ, Moghbel BNA, Niknahad H, Geramizadeh B. Effect of Simvastatin on Cisplatin-induced Nephrotoxicity in Male Rats: Prevention of cisplatin-induced nephrotoxicity. Iran J Pharm Sci. 2011;7(3):165-73.
- 21.Abady AH, Abu-Raghif AR, Qasim BJ. Effects of Atorvastatin against Cisplatin Induced Nephrotoxicity in Rabbits. Int J. 2015;3(10):879-85.
- 22.Fujieda M, Morita T, Naruse K, Hayashi Y, Ishihara M, Yokoyama T, et al. Effect of pravastatin on cisplatin-induced nephrotoxicity in rats. Hum Exp Toxicol. 2011;30(7):603-15. [PubMed ID:20650967]. https://doi.org/10.1177/0960327110376551.
- 23.Iseri S, Ercan F, Gedik N, Yuksel M, Alican I. Simvastatin attenuates cisplatin-induced kidney and liver damage in rats. Toxicology. 2007;230(2-3):256-64. [PubMed ID:17196726]. https://doi.org/10.1016/j.tox.2006.11.073.
- 24.An Y, Xin H, Yan W, Zhou X. Amelioration of cisplatin-induced nephrotoxicity by pravastatin in mice. Exp Toxicol Pathol. 2011;63(3):215-9. [PubMed ID:20060696]. https://doi.org/10.1016/j.etp.2009.12.002.
- 25.Boorla SK, Panchagiri S, Shastrala KK, Bonagiri R, Vangala M. Evaluation of role of atorvastatin in cisplatin induced nephrotoxicity in wistar rats. Global J Pharmacol. 2014;8(2):279-83.
- 26.Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367(1):20-9. [PubMed ID:22762315]. [PubMed Central ID:PMC4398023]. https://doi.org/10.1056/NEJMoa1114248.
- 27.Ramesh G, Reeves WB. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest. 2002;110(6):835-42. [PubMed ID:12235115]. [PubMed Central ID:PMC151130]. https://doi.org/10.1172/JCI15606.
- 28.Kelly KJ, Meehan SM, Colvin RB, Williams WW, Bonventre JV. Protection from toxicant-mediated renal injury in the rat with anti-CD54 antibody. Kidney Int. 1999;56(3):922-31. [PubMed ID:10469360]. https://doi.org/10.1046/j.1523-1755.1999.00629.x.
- 29.Ramesh G, Reeves WB. p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice. Am J Physiol Renal Physiol. 2005;289(1):F166-74. [PubMed ID:15701814]. https://doi.org/10.1152/ajprenal.00401.2004.
- 30.Li S, Wu P, Yarlagadda P, Vadjunec NM, Proia AD, Harris RA, et al. PPAR alpha ligand protects during cisplatin-induced acute renal failure by preventing inhibition of renal FAO and PDC activity. Am J Physiol Renal Physiol. 2004;286(3):F572-80. [PubMed ID:14612380]. https://doi.org/10.1152/ajprenal.00190.2003.
- 31.Maheshwari RA, Sailor GU, Patel L, Balaraman R. Amelioration of cisplatin-induced nephrotoxicity by statins. Indian J Pharmacol. 2013;45(4):354-8. [PubMed ID:24014910]. [PubMed Central ID:PMC3757603]. https://doi.org/10.4103/0253-7613.115016.
- 32.Rasha ME, Dalia SO, Dina MF. Cisplatin-Induced nephrotoxicity in rats: modulatory role of simvastatin and rosuvastatin against apoptosis and inflammation. J Appl Pharm Sci. 2018;8(4):043-50.
Copyright
© 2025, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Similar Articles
Protective Effect of Carvacrol on Renal Functional and Histopathological Changes in Gentamicin-Induced-Nephrotoxicity in Rats
Ahmadvand H, Tavafi M, Asadollahi V, Jafaripour L, Hadipour-Moradi F, et al. Protective Effect of Carvacrol on Renal Functional and Histopathological Changes in Gentamicin-Induced-Nephrotoxicity in Rats. Zahedan J Res Med Sci. 2016;18(4):e6446. doi: https://doi.org/10.17795/zjrms-6446
The Effect of Testosterone and Estradiol on Renal Function Markers in Two Protocols of Cisplatin Induced Nephrotoxicity Models in Surgically Orchiectomized and Ovariectomized Rats
Mazaheri B, Samimiat A, Khosravi M, Talebi A, Nematbakhsh M. The Effect of Testosterone and Estradiol on Renal Function Markers in Two Protocols of Cisplatin Induced Nephrotoxicity Models in Surgically Orchiectomized and Ovariectomized Rats. Int J Cancer Manag. 2019;12(3):e89086. doi: https://doi.org/10.5812/ijcm.89086
Atorvastatin for Prevention of Amikacin-induced Electrolytes Imbalances; a Randomized Clinical Trial
Heydari B, Khalili H, Dashti-Khavidaki S, Beig- Mohammadi MT, Mohammadi M. Atorvastatin for Prevention of Amikacin-induced Electrolytes Imbalances; a Randomized Clinical Trial. Iran J Pharm Res. 2016;15(2):e125174. doi: https://doi.org/10.22037/ijpr.2016.1796
Efficacy of Antioxidant Supplements on Prevention and Amelioration of Cisplatin-Induced Nephrotoxicity: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Kandhare AD, Mukherjee A, Bodhankar SL. Efficacy of Antioxidant Supplements on Prevention and Amelioration of Cisplatin-Induced Nephrotoxicity: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Jundishapur J Nat Pharm Prod. 2019;14(3):e61527. doi: https://doi.org/10.5812/jjnpp.61527
Effect of Testosterone on Cisplatin-Induced Nephrotoxicity in Surgically Castrated Rats
Rostami B, Nematbakhsh M, Pezeshki Z, Talebi A, Sharifi MR, et al. Effect of Testosterone on Cisplatin-Induced Nephrotoxicity in Surgically Castrated Rats. Nephro-Urol Mon. 2014;6(5):e21546. doi: https://doi.org/10.5812/numonthly.21546
- Scopus by DOI: 0
Last Update: 2 weeks ago
- Scopus by Title: 0
Last Update: 2 weeks ago
- Scopus by Title (Ref): 0
Last Update: 2 weeks ago
- CrossRef: 0
Last Update: 6 days ago
- OpenAlex: 0
Last Update: 1 day ago
- OpenCitations: 0
Last Update: 4 days ago
